Your browser doesn't support javascript.
loading
Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties / Profilaxis preexposición (PrEP) frente al VIH: eficacia, seguridad e incertidumbres
Sánchez Conde, Matilde; Vivancos, María Jesús; Moreno Guillén, Santiago.
Affiliation
  • Sánchez Conde, Matilde; Hospital Ramón y Cajal. Infectious Disease Unit. Madrid. Spain
  • Vivancos, María Jesús; Instituto Ramón y Cajal de Investigación Sanitaria (Ramón y Cajal Health Research Institute) (IRYCIS). Madrid. Spain
  • Moreno Guillén, Santiago; University of Alcalá de Henares. Department of Medicine. Madrid. Spain
Farm. hosp ; 41(5): 630-637, sept.-oct. 2017. tab
Article in English | IBECS | ID: ibc-166601
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Despite the global stabilization of the number of new HIV infections in recent years, there has been an increase in new infections among men who have sex with men. This fact indicates the lack of effectiveness of the measures and prevention campaigns established so far for this group. It is therefore necessary to implement alternative preventive measures for them. Pre-exposure pharmacological prophylaxis (PrEP) is one of the best evaluated options and has had high protection rates in both clinical and real-life trials. The strategy has also shown an adequate profile in terms of safety, tolerance, adverse effects and cost-effectiveness in the studies carried out to assess this important topic (AU)
RESUMEN
En los últimos años se ha objetivado un incremento de las nuevas infecciones por el VIH en el grupo de hombres que tienen sexo con hombres, lo que indica la ausencia de eficacia de las campañas y medidas preventivas instauradas en dicho grupo. Es necesario, por tanto, implementar medidas preventivas alternativas, siendo la profilaxis farmacológica pre-exposición (PrEP) una de las opciones mejor evaluadas tanto en ensayos clínicos como en la vida real, habiéndose demostrado tasas de protección superiores al 80% cuando se administra en los casos indicados y con buen cumplimiento terapeútico. La estrategia ha demostrado, además, un perfil adecuado en seguridad, tolerancia y efectos adversos, siendo además coste-efectiva según los estudios realizados para valorar este importante aspecto (AU)
Subject(s)

Full text: Available Collection: National databases / Spain Health context: SDG3 - Health and Well-Being Health problem: Target 3.3: End transmission of communicable diseases Database: IBECS Main subject: HIV Infections / Anti-Retroviral Agents / Pre-Exposure Prophylaxis Limits: Humans Language: English Journal: Farm. hosp Year: 2017 Document type: Article Institution/Affiliation country: Hospital Ramón y Cajal/Spain / Instituto Ramón y Cajal de Investigación Sanitaria (Ramón y Cajal Health Research Institute) (IRYCIS)/Spain / University of Alcalá de Henares/Spain

Full text: Available Collection: National databases / Spain Health context: SDG3 - Health and Well-Being Health problem: Target 3.3: End transmission of communicable diseases Database: IBECS Main subject: HIV Infections / Anti-Retroviral Agents / Pre-Exposure Prophylaxis Limits: Humans Language: English Journal: Farm. hosp Year: 2017 Document type: Article Institution/Affiliation country: Hospital Ramón y Cajal/Spain / Instituto Ramón y Cajal de Investigación Sanitaria (Ramón y Cajal Health Research Institute) (IRYCIS)/Spain / University of Alcalá de Henares/Spain
...